OTCPK:NACN.F

Stock Analysis Report

Executive Summary

National Access Cannabis Corp., through its subsidiary National Access Canada Corporation, owns and operates medical clinics in Canada.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • National Access Cannabis has significant price volatility in the past 3 months.
  • National Access Cannabis is not covered by any analysts.

Share Price & News

How has National Access Cannabis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.2%

OTCPK:NACN.F

-1.2%

US Healthcare

-0.02%

US Market


1 Year Return

-49.6%

OTCPK:NACN.F

-9.4%

US Healthcare

1.6%

US Market

NACN.F underperformed the Healthcare industry which returned -8.4% over the past year.

NACN.F underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

NACN.FIndustryMarket
7 Day-3.2%-1.2%-0.02%
30 Day-0.3%-2.2%2.7%
90 Day-12.4%-1.5%1.4%
1 Year-49.6%-49.6%-8.0%-9.4%3.8%1.6%
3 Yearn/a28.7%23.5%45.2%35.8%
5 Yearn/a62.7%53.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is National Access Cannabis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is National Access Cannabis undervalued based on future cash flows and its price relative to the stock market?

3x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for National Access Cannabis to establish if it is available at moderate discount.

Unable to calculate intrinsic value for National Access Cannabis to establish if it is available at substantial discount.


Price Based on Earnings

National Access Cannabis is loss making, we can't compare its value to the US Healthcare industry average.

National Access Cannabis is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for National Access Cannabis, we can't assess if its growth is good value.


Price Based on Value of Assets

National Access Cannabis is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is National Access Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as National Access Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of NACN.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access National Access Cannabis's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has National Access Cannabis performed over the past 5 years?

-68.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

National Access Cannabis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare National Access Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare National Access Cannabis's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if National Access Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if National Access Cannabis has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if National Access Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is National Access Cannabis's financial position?


Financial Position Analysis

National Access Cannabis's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

National Access Cannabis's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

National Access Cannabis's level of debt (75%) compared to net worth is high (greater than 40%).

Unable to establish if National Access Cannabis's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

National Access Cannabis has less than a year of cash runway based on current free cash flow.

National Access Cannabis has less than a year of cash runway if free cash flow continues to grow at historical rates of 113.3% each year.


Next Steps

Dividend

What is National Access Cannabis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate National Access Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate National Access Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as National Access Cannabis has not reported any payouts.

Unable to verify if National Access Cannabis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as National Access Cannabis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of National Access Cannabis's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Mark Goliger 0

2.1yrs

Tenure

CA$220,385

Compensation

Mr. Mark Goliger has been Chief Executive Officer of National Access Clinic Corp. since August 30, 2017 and has been its Director since September 10, 2018. He has also been the Director of Next Innovations ...


CEO Compensation Analysis

Mark's remuneration is lower than average for companies of similar size in United States of America.

Mark's compensation has increased whilst company is loss making.


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the National Access Cannabis management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

The average tenure for the National Access Cannabis board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellCA$60,22610 May 19
Michael Best
EntityIndividual
Shares100,000
Max PriceCA$0.60
SellCA$138,10621 Sep 18
Derek Ogden
EntityIndividual
Shares190,000
Max PriceCA$0.74

Ownership Breakdown


Management Team

  • Mike Cosic (51yo)

    Chief Financial Officer

    • Tenure: 0.5yrs
  • Christopher Kane

    Chief Operating Officer

    • Tenure: 1.8yrs
  • Michael Saliken

    Corporate Secretary

    • Tenure: 0yrs
  • Lori Bailey

    Senior Vice President of Retail

    • Tenure: 0.5yrs
  • Mark Goliger

    CEO & Director

    • Tenure: 2.1yrs
    • Compensation: CA$220.39k
  • John Gillis

    Consultant

    • Tenure: 1.7yrs
  • Joy Avzar

    Vice President of Legal

    • Tenure: 0.9yrs
  • Matthew Ryan

    Vice President of Marketing

    • Tenure: 0yrs

Board Members

  • Mark Goliger

    CEO & Director

    • Tenure: 2.1yrs
    • Compensation: CA$220.39k
  • Chief Sinclair

    Director

    • Tenure: 1.7yrs
    • Compensation: CA$12.50k
  • Felipe Campusano

    Director

    • Tenure: 1.3yrs
    • Compensation: CA$12.50k
  • Marc Lustig

    Chairman

    • Tenure: 1yrs
    • Compensation: CA$100.00k
  • Rocco Meliambro

    Director

    • Tenure: 2.1yrs
    • Compensation: CA$80.00k

Company Information

National Access Cannabis Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: National Access Cannabis Corp.
  • Ticker: NACN.F
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: CA$90.673m
  • Listing Market Cap: CA$68.323m
  • Shares outstanding: 188.90m
  • Website: https://nationalaccesscannabis.com

Number of Employees


Location

  • National Access Cannabis Corp.
  • 56 Aberfoyle Crescent
  • Suite 200
  • Etobicoke
  • Ontario
  • M8X 2W4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
METATSXV (TSX Venture Exchange)YesCommon StockCACADAug 2017
1HVDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2017
NACN.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2017

Biography

National Access Cannabis Corp., through its subsidiary National Access Canada Corporation, owns and operates medical clinics in Canada. The company provides cannabinoid educational services; and medical ca ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 01:10
End of Day Share Price2019/09/18 00:00
Earnings2019/05/31
Annual Earnings2018/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.